ImmixBio Management Answers Top-Voted Investor Questions at IMMX Investors Day February 1, 2022
Immix Biopharma has hosted an Investors Day event on February 1, 2022, where management responded to top-voted questions from verified shareholders. The session highlighted the company’s commitment to transparency and ongoing communication with investors. ImmixBio is focused on its lead asset, IMX-110, currently in Phase 1b/2a clinical trials for soft tissue sarcoma and rhabdomyosarcoma, supported by orphan drug and rare pediatric designations by the FDA.
- Management engaged with investors at the IMMX Investors Day, enhancing shareholder communication.
- IMX-110 is in clinical trials and has received orphan drug designation from the FDA.
- None.
LOS ANGELES, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, today announced that management has answered top-voted questions submitted by verified IMMX shareholders at the IMMX Investors Day Event on February 1, 2022 at 9:30am ET. ImmixBio welcomed verified shareholders to submit and upvote questions to management from January 6 through January 20, 2022. Answers to top-voted investor questions are viewable at www.immixbio.com/Feb2022QA .
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/303d9588-dc8d-4d64-ba97-77b2410fb313
“Investors are an integral part of our community at ImmixBio,” said Ilya Rachman, MD PhD, CEO of ImmixBio. “Today we addressed questions upvoted by our investors, and are looking forward to an ongoing dialogue through our Q&A platform open to all IMMX shareholders.”
About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio™) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases. Our lead asset IMX-110, currently in Phase 1b/2a clinical trials, holds orphan drug designation (ODD) by the FDA for soft tissue sarcoma, and has received Rare Pediatric Disease Designation (RPDD) for the treatment of rhabdomyosarcoma, a life-threatening form of cancer in children. RPPD qualifies ImmixBio to receive fast track review and a priority review voucher (PRV) at the time of marketing approval of IMX-110. Our proprietary SMARxT Tissue-Specific™ Platform produces drug candidates that circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all 3 components of the tumor micro-environment (TME). We believe ImmixBio’s TME Normalization™ technology severs the lifelines between the tumor and its metabolic and structural support. Learn more at www.immixbio.com .
Forward Looking Statements
This press release contains “forward-looking statements”. Forward-looking statements reflect our current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.
Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Contacts
Immix Biopharma, Inc.
Gabriel Morris
Chief Financial Officer
ir@immixbio.com
+1 (888) 958-1084
FAQ
What is the purpose of the IMMX Investors Day event on February 1, 2022?
What are the key highlights of IMMX's clinical trials?
What designations has IMX-110 received from the FDA?
How does Immix Biopharma engage with its shareholders?
What is Immix Biopharma's focus area?
